Amgen ignites a social fitness movement to support the fight against heart disease and cancer

AmgenAmgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support the fight against heart disease and cancer. Amgen's Breakaway Challenge joins together Breakaway from Cancer® and Breakaway from Heart DiseaseTM and serves as a complementary component to its title sponsorship of the Amgen Tour of California, a world-class cycling event that takes place May 12 - 18, 2019.

The Breakaway Challenge urges participants to turn their walking, running or cycling miles into support for eight nonprofit advocacy organizations that are dedicated to cancer and heart disease research. For a six-week period starting May 1 through June 12, 2019, Amgen will donate $1 dollar for every Breakaway Challenge mile completed by initiative participants, up to $400,000. The donations will be evenly distributed among the eight nonprofits.

"Making a positive difference in the world is at the heart of what we do at Amgen, and it goes beyond developing vital medicines to creating powerful connections with the communities we serve," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. "The Breakaway Challenge encourages personal health while also supporting organizations that work with patients and caregivers in the fight against cancer and heart disease."

Amgen has teamed with Strava, a social fitness app that tracks cycling and running activities, to create the Breakaway Challenge. Strava will aggregate the total miles contributed to the Breakaway Challenge with the goal to collectively reach as many miles as possible with Amgen matching the first 400,000 miles with a $400,000 donation evenly distributed to the nonprofit partners. Participants can join the Challenge by downloading the Strava app to their mobile device and joining the Breakaway Challenge, or by visiting https://www.AmgenBreakawayChallenge.com.

In addition, the Amgen Cycling Club, a non-profit 501(c)(3) organization led by athletes and cyclists who enjoy spending time outdoors on their bikes both in Southern California and around the world, is joining the efforts of the Breakaway Challenge by providing a fundraising platform through the MobileCause app during the Challenge period. The total proceeds raised through the MobileCause fundraising platform during the Breakaway Challenge period will be also evenly distributed to the eight nonprofit Breakaway partners by the Amgen Cycling Club.

About Breakaway Challenge Beneficiaries

Breakaway from Heart DiseaseTM nonprofit partners include the American Heart Association (AHA) and FH Foundation.

Breakaway from Cancer® nonprofit partners include Prevent Cancer Foundation, Cancer Support Community, Patient Advocate Foundation, National Coalition for Cancer Survivorship, Susan G. Komen and Multiple Myeloma Research Foundation.

About Breakaway from Heart DiseaseTM

Breakaway from Heart DiseaseTM encourages Americans to take charge of their risk of heart disease and represents a partnership among Amgen, the American Heart Association and FH Foundation. This initiative is dedicated to empowering everyone to have a plan for good heart health through diagnostic screenings as well as information and tools related to physical activity and healthy eating. Amgen also has a partnership with Schwinn to encourage heart healthy activities like bike riding.

About Breakaway from Cancer®

Founded in 2005, Breakaway from Cancer® is a national initiative to increase awareness of important resources available to people affected by cancer, from prevention through survivorship. Breakaway from Cancer® represents a partnership between Amgen and six nonprofit organizations dedicated to empowering patients with education, resources and hope, offering a broad range of services to people affected by cancer.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...